Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations
Kondo, Takayuki
Banno, Haruhiko
Okunomiya, Taro
Amino, Yoko
Endo, Kayoko
Nakakura, Akiyoshi
Uozumi, Ryuji
Kinoshita, Akemi
Tada, Harue
Morita, Satoshi
Ishikawa, Hidehiro
Shindo, Akihiro
Yasuda, Ken
Taruno, Yosuke
Maki, Takakuni
Suehiro, Takashi
Mori, Kohji
Ikeda, Manabu
Fujita, Koji
Izumi, Yuishin
Kanemaru, Kazutomi
Ishii, Kenji
Shigenobu, Kazue
Kutoku, Yumiko
Sunada, Yoshihide
Kawakatsu, Shinobu
Shiota, Shunji
Watanabe, Toshifumi
Uchikawa, Osamu
Takahashi, Ryosuke
Tomimoto, Hidekazu
Inoue, Haruhisa
京都大学
DOI:10.1136/bmjopen-2021-051343 2021/06